Original ArticleTranslational OncologyPD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project
Keywords
Cited by (0)
Disclosure: Dr. Tsao reports grants and personal fees from AstraZeneca, Merck, and Pfizer and personal fees from Bristol-Myers Squibb and Ventana/Roche outside the submitted work. Dr. Kerr reports personal fees from Bristol-Myers Squibb, Merck Sharp and Dohme, Merck Serono, Roche, and AstraZeneca outside the submitted work. Dr. Beasley reports pathology consulting work from Genentech, Bristol-Myers Squibb, and Merck outside the submitted work. Dr. Botling reports personal fees from AstraZeneca, Merck Sharp and Dohme, Roche, Pfizer, Bristol-Myers Squibb, Boehringer Ingelheim, and Novartis outside the submitted work. Dr. Bubendorf reports grants and personal fees from Roche and Merck Sharp and Dohme and personal fees from Bristol-Myers Squibb and AstraZeneca during the conduct of the study. Dr. Dacic reports personal fees from Bristol-Myers-Squibb and AstraZeneca outside the submitted work. Dr. Lantuejoul reports grants and personal fees from Bristol-Myers Squibb and personal fees from Merck Sharp and Dohme, Roche, and Novartis outside the submitted work. Dr. Mina-Kenudson reports personal fees from Merrimack Pharmaceuticals, H3 Biomedicine, ACD, and Roche outside the submitted work. Dr. Moreira reports personal fees from Genetech outside the submitted work. Dr. Nicholson reports personal fees from Merck, Boehringer Ingelheim, Novartis, AstraZeneca, Bristol-Myers Squibb, Roche, AstraZeneca, and AbbVie and grants and personal fees from Pfizer outside the submitted work. Dr. Poleri reports personal fees from AstraZeneca, Merck, Roche, and Bristol-Myers Squibb outside the submitted work. Dr. Sauter reports stock ownership in Merck, Thermo Fischer Scientific, and Chemed Corporation outside the submitted work. Dr. Thunnissen reports personal fees from HistoGeneX and Ventana Roche during the conduct of the study. Dr. Wistuba reports grants and personal fees from Genentech/Roche, Bristol-Myers Squibb, Astra Zeneca/Medimmune, Pfizer, HTG Molecular, and Merck; personal fees from Boehringer Ingelheim, Medscape, Asuragen, GlaxoSmithKline, and Bayer; and grants from Oncoplex, DepArray, Adaptive, Adaptimmune, Takeda, Amgen, and EMD Serono outside the submitted work. Dr. Yatabe reports personal fees from Merck Sharp and Dohme, Chugai-pharm, AstraZeneca, Pfizer, and Novartis outside the submitted work. Dr. Hirsch is coinventor of a University of Colorado–owned patent titled: “EGFR IHC and. FISH as Predictive Biomarkers for EGFR Therapy.” Dr. Hirsch has participated in advisory boards for Bristol-Myers Squibb, Genentech/Roche, HTG, Lilly, Merck, Pfizer, and Ventana. Dr. Hirsch's laboratory has received research grants (through the University of Colorado) from Genentech, Bristol-Myers Squibb, Lilly, Bayer, and Clovis. The remaining authors declare no conflict of interest.